Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 4.80 |
---|---|
High | 4.80 |
Low | 4.44 |
Bid | 3.90 |
Offer | 5.40 |
Previous close | 4.80 |
Average volume | 19.80k |
---|---|
Shares outstanding | 1.83m |
Free float | 1.83m |
P/E (TTM) | -- |
Market cap | 8.77m USD |
EPS (TTM) | -138.17 USD |
Data delayed at least 15 minutes, as of Oct 09 2024 20:42 BST.
More ▼
Announcements
- Traws Pharma Announces Positive Topline Phase 1 Data for Flu Candidate, Tivoxavir Marboxil
- Traws Pharma Announces Positive Topline Phase 1 Results for COVID Candidate, Ratutrelvir, an Oral Mpro Inhibitor
- Traws Pharma, Inc. Appoints Luba Greenwood to Board of Directors
- Traws Pharma, Inc. Announces Special Shareholders Meeting Results
- Traws Pharma Reports Q2 2024 Financial Results, Provides Recent Business Highlights
- Traws Pharma to Host Corporate Update Call on August 15, 2024, at 8:00 AM ET
- Traws Pharma’s ICAR Poster Highlights Potency of COVID-19 Candidate
- Traws Pharma Reports First Quarter 2024 Financial Results and Provides Business Update
- Traws Pharma Completes First Cohort Dosed in Phase 1 Trial for COVID Therapy
- Traws Pharma Announces New Employee Inducement Grants
More ▼